Abstract
GTPases of the Ras superfamily act as signaling switches, active when bound to GTP and inactive when bound to GDP. There is now considerable evidence that over-activation of Ras-like pathways participates in the development of many cancer types. In particular, GTPases of the Rho family control cell adhesion, survival, motility, and invasion, cell properties dysregulated in most cancer types. Rho activation is triggered by RhoGEFs, most of which form complexes with growth-factor receptors and initiate downstream Rho signaling pathways in response to extracellular clues. As such, RhoGEFs represent attractive targets to inhibit Rho pathways and may have interesting druggability for cancer therapeutics. Here we describe a procedure derived from the yeast two-hybrid system, in which activation of a mammalian Rho GTPase by its cognate RhoGEF is converted into variation in the yeast growth. The experimental design is thus suitable for identiying RhoGEF inhibitors and has been optimized for medium-throughput screening. The major advantages of this method lie in the direct monitoring of GEF activity in a living organism and the rapid detection of false positive hits.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Shirai H, Autieri M, Eguchi S (2007) Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Curr Opin Nephrol Hypertens 16:111–5
Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–7
Bosco EE, Mulloy JC, Zheng Y (2009) Rac1 GTPase: a “Rac” of all trades. Cell Mol Life Sci 66:370–4
Boureux A, Vignal E, Faure S, Fort P (2007) Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol 24:203–16
Rossman KL, Der CJ, Sondek J (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 6:167–80
Meller N, Merlot S, Guda C (2005) CZH proteins: a new family of Rho-GEFs. J Cell Sci 118:4937–46
Diaz-Flores E, Shannon K (2007) Targeting oncogenic Ras. Genes Dev 21:1989–92
Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582:2093–101
Lazer G, Katzav S (2010) Guanine nucleotide exchange factors for RhoGTPases: Good therapeutic targets for cancer therapy? Cell Signal 23:969–79
Leonard DA, Evans T, Hart M, Cerione RA, Manor D (1994) Investigation of the GTP-binding/GTPase cycle of Cdc42Hs using fluorescence spectroscopy. Biochemistry 33:12323–8
Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F, Collard JG (1998) Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol 143:1385–98
Zheng Y, Hart MJ, Cerione RA (1995) Guanine nucleotide exchange catalyzed by dbl oncogene product. Methods Enzymol 256:77–84
De Toledo M, Colombo K, Nagase T, Ohara O, Fort P, Blangy A (2000) The yeast exchange assay, a new complementary method to screen for Dbl-like protein specificity: identification of a novel RhoA exchange factor. FEBS Lett 480:287–92
Blangy A, Bouquier N, Gauthier-Rouviere C, Schmidt S, Debant A, Leonetti JP, Fort P (2006) Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. Biol Cell 98:511–22
Bouquier N, Vignal E, Charrasse S, Weill M, Schmidt S, Leonetti JP, Blangy A, Fort P (2009) A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem Biol 16:657–66
Vives V, Laurin M, Cres G, Larrousse P, Morichaud Z, Noel D, Cote JF, Blangy A (2011) The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. J Bone Miner Res 26(5):1099–110
Vignal E, Blangy A, Martin M, Gauthier-Rouviere C, Fort P (2001) Kinectin is a key effector of RhoG microtubule-dependent cellular activity. Mol Cell Biol 21:8022–34
Acknowledgments
We are indebted to Pauline Larrousse for technical support. This work was funded by institutional grants from CNRS and Montpellier universities, and by contracts from ANR (ANR-06-PCVI-0024), ARC (n° 1048), FRM (DVO20081013473), and Arthritis Fondation Courtin (OPT30713).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
Blangy, A., Fort, P. (2012). Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors. In: Zheng, Y. (eds) Rational Drug Design. Methods in Molecular Biology, vol 928. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-008-3_7
Download citation
DOI: https://doi.org/10.1007/978-1-62703-008-3_7
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-007-6
Online ISBN: 978-1-62703-008-3
eBook Packages: Springer Protocols